

# Introduction to the Treatment of Stimulant Use Disorders

Paxton Bach MD, MSc, ABIM, FRCPC, FASAM Clinical Assistant Professor, Dept. of Medicine University of British Columbia, Vancouver BC June 12<sup>th</sup>, 2023







## Territory Acknowledgement

I respectfully acknowledge the land on which I live and work is the traditional territory of the Coast Salish Peoples, including the unceded homelands of the x<sup>w</sup>məθkwəyəm (Musqueam), Skwxwú7mesh (Squamish), and səl'ílwətat (Tsleil-Waututh) Nations.







#### Disclosures

 Research grants from Michael Smith Health Research BC and the Canadian Institutes of Health Research (CIHR)

The content of this activity may include discussion of off label or investigative drug uses.

The faculty is aware that is their responsibility to disclose this information.







### **Educational Objectives**

- At the conclusion of this activity participants should be able to:
  - Describe the most commonly used unregulated stimulants
  - Appreciate shifts in patterns of use and health consequences over time in North America
  - Adopt a formal approach to the assessment of stimulant use including:
    - Intoxication & withdrawal management
    - Psychosocial treatments
    - Pharmacological treatments
  - Apply a harm reduction lens to stimulant use







## Background





Cocaine/crack

#### Amphetamine/methamphetamine














### Background












#### Background



Increased monoamines = wakefulness, energy, sense of well-being, euphoria, excess sympathetic tone

















## Epidemiology

#### Cocaine seizures



Amphetamine-type stimulant seizures










## Epidemiology










### Epidemiology











#### Overdose Deaths in the US






- Overdose deaths involving cocaine and synthetic opioids
- Overdose deaths involving cocaine without synthetic opioids
- Deaths involving psychostimulants and synthetic opioids
- Deaths involving psychostimulants without synthetic opioids







#### Overdose Deaths in the US



- Patterns of use are highly regional, and may differ significantly among different populations
- Treatment approaches
   must be adapted to local
   resources, needs,
   drivers, patterns of use,
   etc.







#### **Acute Intoxication**

#### **Symptoms**

Mania/paranoia/psychosis

Hypertension, agitation, sweating

Skin-picking/formication (delusions of insects under the skin)

Abnormal movement (choreoathetosis, ataxia)

**Miosis** 

#### Management

Minimize stimulation:

- Quiet location
- Dimly lit
- Cool compress
- Soft voices

Food, water, blankets

Chemical sedation ONLY IF ABSOLUTELY REQUIRED

Benzos are first line


\*How can we distinguish <u>agitation/intoxication</u> from frank <u>psychosis</u>? How does this change management?







#### Treatment









## Psychosocial Treatment

- 1. Contingency management (CM)
- Cognitive behavioural therapy (CBT)
- 3. Community reinforcement approach (CRA)
- 4. 12-step programs
- Motivational interviewing
- Meditation-based therapy
- 7. Non-contingent rewards
- Psychodynamic therapy
- 9. Combinations programs
- 10. Bed-based treatment programs







## Psychosocial Treatment

- 1. Contingency management (CM)
- 2. Cognitive behavioural therapy (CBT)
- 3. Community reinforcement approach (CRA)
- 4. 12-step programs
- Motivational interviewing
- Meditation-based therapy
- 7. Non-contingent rewards
- Psychodynamic therapy
- 9. Combinations programs
- 10. Bed-based treatment programs







## **Contingency Management**

- Uses principles of operant conditioning to <u>reduce</u> <u>reinforcement provided by drug</u> <u>use while simultaneously</u> <u>increasing reinforcement for</u> <u>healthier activities</u>
- Applies contingencies in the form of positive rewards in order to promote goals such as reduction in substance use or retention in care
  - Voucher or cash based
  - Escalating rewards or "fishbowl"

 In a meta-analysis of 50 RCTs effects of contingency management on abstinence at the end of treatment NNT = 5.44

Limitations: questionable long-term benefits, limited uptake due to moral objections







## Cognitive Behavioural Therapy

- Short-term approach to help identify the <u>thoughts</u>, <u>feelings</u>, <u>and</u> <u>actions</u> that occur both before and after stimulant use
- Goal is to unlearn established habits and behaviours associated with use and learn more functional coping skills
- Helps patients to recognize situations in which they are likely to use drugs and to use coping skills to change their behaviour

- In a meta-analysis of 50 RCTs effects of CBT on abstinence at the end of treatment nonsignificant
- Individual studies have shown some benefit

Limitations: inconsistent results in the literature, requires specialist training







### Community Reinforcement Approach

- Multicomponent approach that considers <u>how environment</u> influences habitual substance use
- Interventions include functional analysis, coping-skills training, and social, familial, recreational, and vocational reinforcements
- Focused on skills training, improving relations, employment and vocational counselling, and cultivating new activities and social networks

 In a meta-analysis of 50 RCTs effects of CM + CRA were strongest with NNT = 4.07 at end of treatment, NNT = 3.68 at longest follow-up

Limitations: complex and multilayered, resource intensive, requires specific training







## Choosing an Intervention

# **No guidance** as to which intervention should be considered first

Include a physical and psychosocial assessment to help inform options

Follow a personcentred and evidence-informed approach Discuss treatment options and rationale, including weighing of risks and benefits

Should be informed by the individual's treatment goals and preferences










## Evidence for Pharmacotherapy



# Conclusions are <u>limited</u>







## Pharmacotherapy\*

Cocaine Use	Amphetamine Use
Bupropion	Mirtazapine
<ul><li>Modafinil</li><li>Without co-occurring alcohol use disorder</li></ul>	<ul> <li>Bupropion (+/- Naltrexone-XR)</li> <li>Monotherapy for low to moderate use only</li> <li>Combination therapy for those with alcohol use disorder</li> </ul>
<ul><li>Topiramate (+/- Mixed</li><li>Amphetamine Salts)</li><li>Consider with co-occurring alcohol use disorder</li></ul>	<ul><li>Topiramate</li><li>Consider with co-occurring alcohol use disorder</li></ul>
<ul><li>Amphetamine formulations</li><li>At or above highest recommended dose</li></ul>	<ul><li>Methylphenidate</li><li>At or above highest recommended dose</li></ul>


\*From DRAFT ASAM/AAAP guidelines for public comment







## Harm Reduction Principles



### **Additional Tips**

- Stimulant withdrawal can be prolonged and miserable, don't minimize it
- Stimulants can be contaminated with fentanyl, counsel people accordingly on minimizing their overdose risk
- Beta-blockers <u>should not</u> be avoided in people who use stimulants when medically indicated

Start by trying to understand the role that a stimulant plays in someone's life and your treatment options will often become much clearer







## Summary

- Cocaine and crystal methamphetamine are the most commonly used unregulated stimulants in North America
- Both prevalence and consequences of stimulant use are increasing and are contributing to the overdose crisis (especially methamphetamine)
- Management of intoxication and withdrawal is generally with supportive care
- Psychosocial and pharmacologic treatment options for stimulant use disorder do exist, contingency management is the best evidenced tool
- Harm reduction counseling is a critical component of care







#### References

- Bach P et al. (2022). British Columbia Centre on Substance Use Stimulant Use Disorder Practice Update. BCCSU, Vancouver, BC, Canada.
- Batki S et al. (2023). The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (DRAFT for Public Comment). American Society of Addiction Medicine / American Association of Addiction Psychiatrists.
- Crispo J et al. (2023). Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020. Can J Psychiatry, Mar 8;7067437231158933.
- De Crescenzo F et al. (2018). Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS Med, 15(12):e1002715.
- NIHCM, Beyond opioids: Rapid increase in drug deaths involving stimulants (National Institute for Health Care Management, 2021).
- NIH publication; no. 00-4871. The Brain Understanding Neurobiology Through the Study of Addiction (National Institutes of Drug Abuse, 2000).
- Tardelli V et al. (2020). Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology, 237(8):2233-2255.
- UNODC, World Drug Report 2022 (United Nations publication, 2022).
- Vearrier D et al. (2012). Methamphetamine: History, Pathophysiology, Adverse Health Effects, Current Trends, and Hazards Associated with the Clandestine Manufacture of Methamphetamine. Dis Mon, 58:38-89.
- Winkelman T et al. (2018). Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States. JAMA Netw Open, 1(6):e183758.







## 1. Which of the following is NOT a commonly used stimulant-type substance?

- a) Cocaine
- b) Crystal methamphetamine
- c) Phencyclidine
- d) MDMA

Correct Answer Feedback: That's correct! Phencyclidine is classified as a dissociative anaesthetic, all other choices are classified as stimulants. Incorrect Answer Feedback: That's incorrect. Phencyclidine is classified as a dissociative anaesthetic, all other choices are classified as stimulants.

**Reference**: Vearrier D et al. (2012). Methamphetamine: History, Pathophysiology, Adverse Health Effects, Current Trends, and Hazards Associated with the Clandestine Manufacture of Methamphetamine. Dis Mon, 58:38-89.







- 2. Stimulants effects are mediated by which neurotransmitters/receptors in the central nervous system?
  - a) Mu-opioid receptors
  - b) Dopamine receptors
  - c) NMDA receptors
  - d) GABA receptors

**Correct Answer Feedback**: That's correct! Stimulants exert their effects on monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin. **Incorrect Answer Feedback**: That's incorrect. Stimulants exert their effects on monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin.

**Reference**: Vearrier D et al. (2012). Methamphetamine: History, Pathophysiology, Adverse Health Effects, Current Trends, and Hazards Associated with the Clandestine Manufacture of Methamphetamine. Dis Mon, 58:38-89.







- 3. What percentage of psychostimulant-related overdose deaths in the US did not involve a synthetic opioid in 2020?
  - a) 10%
  - b) 20%
  - c) 50%
  - d) 90%

**Correct Answer Feedback**: That's correct! Approximately 50% of psychostimulant-related deaths in the US in 2020 did not involve a synthetic opioid.

**Incorrect Answer Feedback**: That's incorrect. Approximately 50% of psychostimulant-related deaths in the US in 2020 did not involve a synthetic opioid.

**Reference**: UNODC, World Drug Report 2022 (United Nations publication, 2022).







## 4. Which of the following is the best evidenced psychosocial intervention for the treatment of stimulant use disorder?

- a) Contingency management
- b) 12-step program
- c) Bed-based treatment programs
- d) Cognitive behavioural therapy

**Correct Answer Feedback**: That's correct! Cognitive behavioural therapy is the best evidenced treatment for stimulant disorder, especially when combined with s community reinforcement approach.

**Incorrect Answer Feedback**: That's incorrect. Cognitive behavioural therapy is the best evidenced treatment for stimulant disorder.

**Reference**: De Crescenzo F et al. (2018). Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS Med, 15(12):e1002715.







## 5. Which of these medications has some evidence suggesting effectiveness in the treatment of stimulant use disorders?

- a) Dextroamphetamine
- b) Ranitidine
- c) Cyclobenzaprine
- d) Buprenorphine

**Correct Answer Feedback**: That's correct! Prescribed psychostimulants such as dextroamphetamine have some evidence supporting their role in the treatment of stimulant use disorders, especially cocaine use disorder.

**Incorrect Answer Feedback**: That's incorrect. Prescribed psychostimulants such as dextroamphetamine have some evidence supporting their role in the treatment of stimulant use disorders, the other medications do not.

**Reference**: Tardelli V et al. (2020). Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology, 237(8):2233-2255.







- 6. Which of the following is NOT a recommended harm reduction intervention for people who use stimulants.
  - a) Sterile injection equipment
  - b) Naloxone kits/nasal spray
  - c) Fentanyl test strips
  - d) Lubricated eye drops

**Correct Answer Feedback**: That's correct! Sterile injection equipment, fentanyl test strips, and naloxone can all be helpful harm reductions for people who use stimulants.

**Incorrect Answer Feedback**: That's incorrect. Sterile injection equipment, fentanyl test strips, and naloxone can all be helpful harm reductions for people who use stimulants.

**Reference**: Bach P et al. (2022). British Columbia Centre on Substance Use Stimulant Use Disorder Practice Update. BCCSU, Vancouver, BC, Canada.





